Pipeline

Peptide Therapeutic Programs

Program
Development Partner
Therapeutic Area
Discovery
Preclinical
Phase I
Phase II
Phase III
Program 1
Bristol Myers Squibb
ImmunoOncology
HA Program (PD-001)
Not yet partnered (In-house)
Influenza
Program 3
Partner not disclosed yet
Undisclosed
Program 4
Partner not disclosed yet
Undisclosed
Program 5
Partner not disclosed yet
Undisclosed
Program 6
Partner not disclosed yet
Undisclosed
Program 7
Partner not disclosed yet
Undisclosed
Program 8
Partner not disclosed yet
Undisclosed
Program 9
Partner not disclosed yet
Undisclosed
Program 10
Partner not disclosed yet
Undisclosed
Program 11
Partner not disclosed yet
Undisclosed
Program 12
Partner not disclosed yet
Undisclosed
Program 13
Partner not disclosed yet
Undisclosed
Program 14
Partner not disclosed yet
Undisclosed
Program 15
Partner not disclosed yet
Undisclosed
Program 16
Partner not disclosed yet
Undisclosed
Program 17
Partner not disclosed yet
Undisclosed
Program 18
Partner not disclosed yet
Undisclosed
Program 19
Partner not disclosed yet
Undisclosed
Program 20
Partner not disclosed yet
Undisclosed
Program 21
Partner not disclosed yet
Undisclosed
Program 22
Partner not disclosed yet
Undisclosed
Program 23
Partner not disclosed yet
Undisclosed
Program 24
Partner not disclosed yet
Undisclosed
Program 25
Partner not disclosed yet
Undisclosed
Program 26
Partner not disclosed yet
Undisclosed
Program 27
Partner not disclosed yet
Undisclosed
Program 28
Partner not disclosed yet
Undisclosed
Program 29
Partner not disclosed yet
Undisclosed
Program 30
Partner not disclosed yet
Undisclosed
Program 31
Partner not disclosed yet
Undisclosed
Program 32
Partner not disclosed yet
Undisclosed
Program 33
Partner not disclosed yet
Undisclosed
Program 34
Partner not disclosed yet
Undisclosed
Program 35
Partner not disclosed yet
Undisclosed
Program 36
Partner not disclosed yet
Undisclosed
Program 37
Partner not disclosed yet
Undisclosed
Program 38
Partner not disclosed yet
Undisclosed

Small Molecule Therapeutic Programs

Program
Partner
Therapeutic Area
Discovery
Preclinical
Phase I
Phase II
Phase III
Program 1
Partner not disclosed yet
Undisclosed
Program 2
Not yet partnered (In-house)
Undisclosed

Peptide Drug Conjugate Programs

Program
Partner
Therapeutic Area
Discovery
Preclinical
Phase I
Phase II
Phase III
HER2
Not yet partnered (In-house)
Oncology
Program 2
Not yet partnered (In-house)
Undisclosed
Program 3
Not yet partnered (In-house)
Undisclosed
Program 4
Not yet partnered (In-house)
Undisclosed
Program 5
Not yet partnered (In-house)
Undisclosed
Program 6
Not yet partnered (In-house)
Undisclosed
Program 7
Not yet partnered (In-house)
Undisclosed
Program 8
Not yet partnered (In-house)
Undisclosed
Program 9
Not yet partnered (In-house)
Undisclosed
Program 10
Not yet partnered (In-house)
Undisclosed
Program 11
Not yet partnered (In-house)
Undisclosed
Program 12
Not yet partnered (In-house)
Undisclosed
Program 13
Not yet partnered (In-house)
Undisclosed
Program 14
Not yet partnered (In-house)
Undisclosed
Program 15
Not yet partnered (In-house)
Undisclosed
Program 16
Not yet partnered (In-house)
Undisclosed
Program 17
Not yet partnered (In-house)
Undisclosed
Program 18
Not yet partnered (In-house)
Undisclosed
Program 19
Not yet partnered (In-house)
Undisclosed